Amgen (AMGN) Misses Q2 EPS by 1c; updates guidance

Amgen (NASDAQ: AMGN) reported Q2 EPS of $4.97, $0.01 worse than the analyst estimate of $4.98. Revenue for the quarter came in at $8.39 billion versus the consensus estimate of $8.35 billion.

GUIDANCE:

Amgen sees FY2024 EPS of $19.10-$20.10, versus the consensus of $17.87. Amgen sees FY2024 revenue of $32.8-33.8 billion, versus the consensus of $30.3 billion.

For earnings history and earnings-related data on Amgen (AMGN) click here.

You May Also Be Interested In

• Goldman Sachs Double Upgrades Bradsaude SA (SAUD3:BZ) to Buy
• Morgan Stanley Upgrades MGM Chin (2282:HK) (MCHVY) to Overweight
• JPMorgan Upgrades SHIFT UP Corp (462870:KS) to Overweight